[company_age]9.0[/company_age][employees]11-50 employees[/employees][funding]Series B[/funding][description]STORM Therapeutics is a clinical-stage biotechnology company pioneering the development of novel therapies that target RNA modifying enzymes (RMEs) for the treatment of cancer and other diseases. Founded in 2015, STORM has established a first-mover advantage in the field of RNA epigenetics, leveraging its proprietary drug discovery and RNA analytics platform to identify and validate novel therapeutic targets. The company\[/description][ps]Novel therapies targeting RNA modifying enzymes (RMEs) for oncology, inflammation, viral infections, and CNS diseases.[/ps]